BPIFB2

Across TCGA pan-cancer cohorts, BPIFB2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BPIFB2 data layer compared with 17 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher BPIFB2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BPIFB2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

ESCA, LGG, and SARC are the cancer types where BPIFB2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.099	0.685	<.001	33	view →
LGG	OS	Median	All	0.208	0.896	<.001	12	view →
SARC	OS	Median	All	0.205	0.826	<.001	9	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.566	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BPIFB2–ESCA (OS)

Open the ESCA breakdown →